Inoxon

Inoxon injection can be administered intramuscularly (IM) or intravenously (IV). For IM administration, dissolve in lidocaine and inject deep into a large muscle. For IV administration, dissolve in water for injection or normal saline and administer as a slow IV injection over 2-4 minutes or as an IV infusion over 30 minutes.

Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell lysis and death.

• Known hypersensitivity to ceftriaxone, any other cephalosporin, or to penicillin antibiotics.
• Neonates (≤28 days) with hyperbilirubinemia, especially premature neonates, due to the risk of bilirubin encephalopathy.
• Concomitant use with intravenous calcium-containing solutions in neonates (≤28 days).

Store below 30°C in a dry place, protected from light. Keep out of reach of children. Reconstituted solutions should be used immediately or stored as per manufacturer's guidelines (e.g., stable for 6 hours at room temperature or 24 hours in a refrigerator).

In cases of overdose, symptoms may include nausea, vomiting, and diarrhea. Management is primarily symptomatic and supportive. There is no specific antidote. Hemodialysis or peritoneal dialysis is not effective in removing Ceftriaxone from the body.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but adequate and well-controlled studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed and the potential benefits outweigh the risks. Ceftriaxone is excreted in breast milk in low concentrations; caution should be exercised when administering to a nursing mother.

• Known hypersensitivity to ceftriaxone, any other cephalosporin, or to penicillin antibiotics.
• Neonates (≤28 days) with hyperbilirubinemia, especially premature neonates, due to the risk of bilirubin encephalopathy.
• Concomitant use with intravenous calcium-containing solutions in neonates (≤28 days).

Store below 30°C in a dry place, protected from light. Keep out of reach of children. Reconstituted solutions should be used immediately or stored as per manufacturer's guidelines (e.g., stable for 6 hours at room temperature or 24 hours in a refrigerator).

In cases of overdose, symptoms may include nausea, vomiting, and diarrhea. Management is primarily symptomatic and supportive. There is no specific antidote. Hemodialysis or peritoneal dialysis is not effective in removing Ceftriaxone from the body.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but adequate and well-controlled studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed and the potential benefits outweigh the risks. Ceftriaxone is excreted in breast milk in low concentrations; caution should be exercised when administering to a nursing mother.